A carregar...
CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES
Histone deacetylase inhibition is a potential new strategy for the treatment of glioblastoma (GBM) and FDA-approved for multiple myeloma. However, resistance to therapy is a major issue. By conducting a global transcriptome with subsequent gene set enrichment analysis in stem-like GBM cells and PDX...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217162/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.156 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|